160 reports of this reaction
1.9% of all REGADENOSON reports
#15 most reported adverse reaction
UNRESPONSIVE TO STIMULI is the #15 most commonly reported adverse reaction for REGADENOSON, manufactured by Astellas Pharma US, Inc.. There are 160 FDA adverse event reports linking REGADENOSON to UNRESPONSIVE TO STIMULI. This represents approximately 1.9% of all 8,610 adverse event reports for this drug.
Patients taking REGADENOSON who experience unresponsive to stimuli should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
UNRESPONSIVE TO STIMULI is a less commonly reported adverse event for REGADENOSON, but still significant enough to appear in the safety profile.
In addition to unresponsive to stimuli, the following adverse reactions have been reported for REGADENOSON:
The following drugs have also been linked to unresponsive to stimuli in FDA adverse event reports:
UNRESPONSIVE TO STIMULI has been reported as an adverse event in 160 FDA reports for REGADENOSON. This does not prove causation, but indicates an association observed in post-market surveillance data.
UNRESPONSIVE TO STIMULI accounts for approximately 1.9% of all adverse event reports for REGADENOSON, making it a notable side effect.
If you experience unresponsive to stimuli while taking REGADENOSON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.